Latest UCB Stories
GIA announces the release of a comprehensive global report on the CNS Therapeutics.
NEW YORK, Feb. 12, 2015 /PRNewswire/ -- Royalty Pharma is pleased to announce that George Lloyd has been named General Counsel of Royalty Pharma effective immediately.
LONDON, February 10, 2015 /PRNewswire/ -- Report Details What are the commercial prospects for pharmaceutical [https://www.visiongain.com/Pharma/47/Reports
NEW YORK, Jan.
- Atlanta-based Collaboration Will Explore the Potential of Big Data to Help Inform Treatment Decisions for People Living with Epilepsy ATLANTA, Dec.
- 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) BRUSSELS, Dec.
BOSTON and NEW YORK, Nov.
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.
- VIMPAT® (lacosamide) C-V approved in the U.S. as monotherapy in the treatment of partial-onset seizures in adults with epilepsy(1) BRUSSELS, Sept.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.